title: Plasma-diluted thrombin time to measure dabigatran concentrations during dabigatran etexilate therapy.
abstract: New anticoagulants, like the orally available direct thrombin inhibitor (DTI) dabigatran etexilate, have recently been introduced into the market for venous thromboembolic prophylaxis and for stroke prevention in atrial fibrillation. While dabigatran has been approved for use without the need for routine therapeutic monitoring, there are clinical scenarios in which monitoring can help guide clinical management. We report herein the application of a recently described plasma-diluted thrombin time (DTI assay) used to monitor intravenous DTI as a useful and easily implemented method to monitor oral DTIs.
authors.affiliation: Laboratory Medicine, University of Washington, Seattle, USA.
authors.forename: Scott T
authors.initials: ST
authors.lastname: Avecilla
authors.forename: Chris
authors.initials: C
authors.lastname: Ferrell
authors.forename: Wayne L
authors.initials: WL
authors.lastname: Chandler
authors.forename: Morayma
authors.initials: M
authors.lastname: Reyes
mesh_terms: D058833:Antithrombin Proteins / Q000008:administration & dosage / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000188:drug therapy*; D001562:Benzimidazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D000069604:Dabigatran; D004305:Dose-Response Relationship, Drug; D006801:Humans; D011725:Pyridines / Q000008:administration & dosage / Q000627:therapeutic use*; D020521:Stroke / Q000517:prevention & control*; D013918:Thrombin Time
chemical_list: D058833:Antithrombin Proteins; D001562:Benzimidazoles; D011725:Pyridines; D000069604:Dabigatran